Research Article

Improved Efficacy of Transcatheter Arterial Chemoembolization Using Warmed Miriplatin for Hepatocellular Carcinoma

Table 2

Results of logistic regression analysis.

FactorsOdds ratio (95% CI)P value

Sex (female)0.39 (0.12–1.17)0.10
HBV infection0.30 (0.046–1.49)0.16
Tumor size (mm2)1.00 (1.00-1.00)0.13
AFP (ng/mL)1.00 (1.00-1.00)0.16
DCP (mAU/mL)1.00 (1.00-1.00)0.14
BCLC stage C0.77 (0.24–2.43)0.66
BCLC stage D36.55 (0.70–3635.77)0.078
History of TACE0.78 (0.27–2.24)0.64
Warming miriplatin12.35 (2.90–90.0)0.0028**
Miriplatin dose (mg)0.99 (0.96–1.01)0.43
Severe hepatic arterial damage0.59 (0.10–2.73)0.52

.
CI: confidence interval; HBV: hepatitis B virus; AFP: alpha-fetoprotein; DCP: des-gamma-carboxyprothrombin; BCLC: Barcelona Clinic Liver Cancer; TACE: transcatheter arterial chemoembolization.